A Case Report Form Packet Contents
|
|
- Katherine Hensley
- 6 years ago
- Views:
Transcription
1 A Case Report Form Packet Contents Revision History... 3 Institutional Contacts... 4 On-Study (page 1 of 2)... 5 On-Study (page 2 of 2)... 6 Surgery: Left Breast (page 1 of 2)... 7 Surgery: Left Breast (page 2 of 2)... 8 Surgery: Right Breast (page 1 of 2)... 9 Surgery: Right Breast (page 2 of 2) Radiation Therapy: Left Breast (page 1 of 2) Radiation Therapy: Left Breast (page 2 of 2) Radiation Therapy: Right Breast (page 1 of 2) Radiation Therapy: Right Breast (page 2 of 2) On-Study: Neoadjuvant/Adjuvant Therapy Adverse Events: Baseline Supporting Documentation: Baseline Specimen Submission: Tissue (Baseline) Specimen Submission: Blood (Baseline) Specimen Submission: Urine (Baseline) PRO/QOL: Registration Fatigue/ Uniscale Assessment Compliance Patient Status: Baseline Intervention Intervention: Dose Modifications Adverse Events: Solicited (page 1 of 2) Adverse Events: Solicited (page 2 of 2) Adverse Events: Other Supporting Documentation Specimen Submission: Blood (24 months post registration) Specimen Submission: Urine (24 months post registration) PRO/QOL: Booklet Compliance Patient Status: Treatment (Intervention) tice of Invasive Breast Cancer Recurrence tice of New Primary tice of New DCIS Off Treatment
2 A Case Report Form Packet Patient Status: Survival and Disease Status Follow-Up Adverse Events: Late Consent Withdrawal Consent Withdrawal: QOL Only Consent Withdrawal: Specimen Only Consent Withdrawal: All Follow-Up Lost to Follow-Up
3 Revision History Version Date Description of Changes 1 12/08/2016 Activation 2 12/15/2017 Surgery: Left Breast Changed question text under Final Margins If the tumor does not involve the margins how close is the nearest margin? (check one) < 1mm 1-2mm > 2mm Changed dictionary values on the following question: Tumor singularity (check one) Solitary Multicentric Surgery: Right Breast Changed question text under Final Margins If the tumor does not involve the margins how close is the nearest margin? (check one) < 1mm 1-2mm > 2mm Changed dictionary values on the following question: Tumor singularity (check one) Solitary Multicentric Consent Withdrawal Removed incorrect instructions regarding Clinical Followup 3
4 Institutional Contacts INSTRUCTIONS: Use this form to identify who the Data Manager should contact for quality assurance purposes. Please update this information if there are any changes to the contact information. Cycle/Visit 0 (Baseline) (derived field) CRA Name (first, last) Phone (example, ) LEAD CRA Name (first, last) Phone (example, ) 4
5 On-Study (page 1 of 2) Cycle/Visit 0 (Baseline) (derived field) DISEASE STATUS Previous surgery related to this tumor (biopsies, resections, bypass, explorations, etc.) (check one) Yes (If yes), tumor laterality (check one) Right Left Bilateral Left breast (check one) Yes Right breast (check one) Yes Prior radiation therapy for this tumor (check one) Yes (If yes), tumor laterality Left breast (check one) Yes Right breast (check one) Yes Did the patient receive neoadjuvant/adjuvant chemotherapy? (check one) Yes (If yes), last date neoadjuvant/adjuvant chemotherapy administered (dd MMM yyyy) - - COMORBID CONDITIONS Prior history of hypertension treated with medication (check one) Yes Prior history of gastric/duodenal ulcers (non-bleeding) (check one) Yes PATIENT HISTORY Prior history of NSAID and/or aspirin use (check one) Yes (If yes), average number of times used per week in the last month PRIOR THERAPY Prior therapy (check one) Yes (If yes), Endocrine therapy (check one) Yes mtor inhibitors (Everolimus, etc. including placebo controlled trials) (check one) Yes CDK 4/6 inhibitors (Palbociclib, Abemaciclib, LEE011, etc. including placebo controlled trials) (check one) Yes Other therapy (check one) Yes Other, specify PRIOR CANCERS Has the patient had any (other) prior (invasive) cancer diagnosed? (check one) Yes (If yes), site of prior cancer (If yes), prior cancer diagnosis date (dd MMM yyyy) - - 5
6 On-Study (page 2 of 2) PATIENT CHARACTERISTICS AT RANDOMIZATION Height (without shoes) (cm) Weight (at randomization, with indoor clothing and without shoes). (kg) BMI (at randomization). ECOG Performance Status (check one) Menopausal status (check one) Pre (< 6 mo since LMP and no prior bilateral ovariectomy AND not on estrogen replacement) Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy) Above categories not applicable AND Age < 50 Above categories not applicable AND Age >= 50 COMPANION STUDIES Did the patient consent to the optional specimen banking? (check one) Yes Did the patient consent to the optional PRO/QOL study? (check one) Yes 6
7 Surgery: Left Breast (page 1 of 2) INSTRUCTIONS: For date fields, UN should be entered if day (dd) is unknown; UNK should be selected if month (MMM) is unknown; Year (yyyy) cannot be entered as unknown. Cycle/Visit 0 (Baseline) (derived field) Primary tumor diagnosis date (dd MMM yyyy) - - Tumor singularity (check one) Solitary Multicentric Longest diameter of lesion(s). (cm) Pre-operative therapy (check one) Yes (If yes), Type of preoperative therapy Chemotherapy Hormonal (add a log line for each type of preoperative therapy) Most extensive definitive surgery for breast (check one) Most extensive definitive surgery for axilla (check one) Date of primary surgery (dd MMM yyyy) - - Sentinel lymph node (SLN) biopsy (check one) Yes Axillary lymph node dissection (ALND) (check one) Yes (If SLN biopsy and/or ALND dissection), Partial mastectomy/lumpectomy/excisional biopsy Modified radical mastectomy Skin sparing or nipple sparing mastectomy Sentinel node biopsy Level I and II axillary dissection ne Total number of lymph nodes examined (include both SLN and ALND results) Total number of positive nodes (include both SLN and ALND results) Was breast/chest wall re-excision/reoperation necessary? (check one) Yes Date of last breast tumor surgery (dd MMM yyyy) - - Did the patient undergo contralateral prophylactic mastectomy (bilateral mastectomy)? (check one) Yes FINAL MARGINS (INVASIVE OR NON-INVASIVE) Does the tumor involve the surgical margin(s)? (check one) Yes (If yes), describe the extent of margin involvement (check one) Single margin, focal Single margin, extensive Multiple margins (If yes), describe the cancer histology of margin involvement (check one) Invasive tumor (with or without DCIS/LCIS) DCIS If the tumor does not involve the margins how close is the nearest margin? (check one) < 1mm 1-2mm > 2mm 7
8 Surgery: Left Breast (page 2 of 2) TUMOR HISTOLOGY Estrogen receptor status (per institutional guidelines) (check one) Positive Negative Progesterone receptor status (per institutional guidelines) (check one) Positive Negative DISEASE STAGE Pathologic T Stage (check one) TX T0 Tis T1 T2 T3 T4 Pathologic N Stage (check one) pnx pn0 pn0(i+) pn0(i-) pn1 pn1mi pn2 pn3 Did the patient receive neoadjuvant treatment? (check one) Yes (If yes), Clinical T Stage (prior to neoadjuvant treatment) (check one) TX T0 Tis T1 T2 T3 T4 (If yes), Clinical N Stage (check one) NX N0 N1 N2 N3 BREAST RECONSTRUCTION Did the patient receive breast reconstruction? (check one) Yes, immediate Yes, delayed (If yes, immediate or yes, delayed), Type of breast reconstruction (check one) Breast implant Free flap Pedicle flap Reduction pattern / mammoplasty Tissue expander Date of last breast reconstruction surgery (dd MMM yyyy) - - 8
9 Surgery: Right Breast (page 1 of 2) INSTRUCTIONS: For date fields, UN should be entered if day (dd) is unknown; UNK should be selected if month (MMM) is unknown; Year (yyyy) cannot be entered as unknown. Cycle/Visit 0 (Baseline) (derived field) Primary tumor diagnosis date (dd MMM yyyy) - - Tumor singularity (check one) Solitary Multicentric Longest diameter of lesion(s). (cm) Pre-operative therapy (check one) Yes (If yes), Type of preoperative therapy Chemotherapy Hormonal (add a log line for each type of preoperative therapy) Most extensive definitive surgery for breast (check one) Most extensive definitive surgery for axilla (check one) Date of primary surgery (dd MMM yyyy) - - Sentinel lymph node (SLN) biopsy (check one) Yes Axillary lymph node dissection (ALND) (check one) Yes (If SLN biopsy and/or ALND dissection), Partial mastectomy/lumpectomy/excisional biopsy Modified radical mastectomy Skin sparing or nipple sparing mastectomy Sentinel node biopsy Level I and II axillary dissection ne Total number of lymph nodes examined (include both SLN and ALND results) Total number of positive nodes (include both SLN and ALND results) Was breast/chest wall re-excision/reoperation necessary? (check one) Yes Date of last breast tumor surgery (dd MMM yyyy) - - Did the patient undergo contralateral prophylactic mastectomy (bilateral mastectomy)? (check one) Yes FINAL MARGINS (INVASIVE OR NON-INVASIVE) Does the tumor involve the surgical margin(s)? (check one) Yes (If yes), describe the extent of margin involvement (check one) Single margin, focal Single margin, extensive Multiple margins (If yes), describe the cancer histology of margin involvement (check one) Invasive tumor (with or without DCIS/LCIS) DCIS If the tumor does not involve the margins how close is the nearest margin? (check one) < 1mm 1-2mm > 2mm 9
10 Surgery: Right Breast (page 2 of 2) TUMOR HISTOLOGY Estrogen receptor status (per institutional guidelines) (check one) Positive Negative Progesterone receptor status (per institutional guidelines) (check one) Positive Negative DISEASE STAGE Pathologic T Stage (check one) TX T0 Tis T1 T2 T3 T4 Pathologic N Stage (check one) pnx pn0 pn0(i+) pn0(i-) pn1 pn1mi pn2 pn3 Did the patient receive neoadjuvant treatment? (check one) Yes (If yes), Clinical T Stage (prior to neoadjuvant treatment) (check one) TX T0 Tis T1 T2 T3 T4 (If yes), Clinical N Stage (check one) NX N0 N1 N2 N3 BREAST RECONSTRUCTION Did the patient receive breast reconstruction? (check one) Yes, immediate Yes, delayed (If yes, immediate or yes, delayed), Type of breast reconstruction (check one) Breast implant Free flap Pedicle flap Reduction pattern / mammoplasty Tissue expander Date of last breast reconstruction surgery (dd MMM yyyy)
11 Radiation Therapy: Left Breast (page 1 of 2) INSTRUCTIONS: For date fields, UN should be entered if day (dd) is unknown; UNK should be selected if month (MMM) is unknown; Year (yyyy) cannot be entered as unknown. Cycle/Visit 0 (Baseline) (derived field) Radiation completed (check one) Yes (If no), radiation ongoing/planned (check one) Yes Type of radiation received (check one) Radiation therapy start date (dd MMM yyyy) - - Radiation therapy end date (dd MMM yyyy) - - Whole breast irradiation only Whole breast irradiation and regional nodal irradiation Partial breast irradiation Post mastectomy irradiation chest wall only Post mastectomy irradiation chest wall and regional nodes I. RADIATION DOSE TO WHOLE BREAST OR CHEST WALL Is total dose prior to boost known? (check one) Yes (If yes). total dose prior to boost. (Gy) Is total # (number) of fractions known? (check one) Yes (If yes), total number of fractions Boost to lumpectomy cavity or chest wall scar Was a boost given? (check one) Yes Is RT total dose to boost field known? (check one) Yes (If yes), RT total dose to boost field. (Gy) Is total # (number) of fractions to boost field known? (check one) Yes (If yes), total number of fractions to boost field Time point (check one) Intra-Op Post-Op II. RADIATION DOSE TO TARGETED REGIONAL NODES dal regions targeted Axillary Supraclavicular/axillary level 3 Internal mammary nodes (add a log line for each nodal region targeted) Is total dose to nodal regions known? (check one) Yes (If yes), total dose to nodal regions. (Gy) Is total # (number) of fractions known? (check one) Yes (If yes), total # (number) of fractions 11
12 Radiation Therapy: Left Breast (page 2 of 2) III. PARTIAL BREAST IRRADIATION Is (PBI) total dose delivered known? (check one) Yes (If yes), PBI total dose delivered. (Gy) Is (PBI) total # (number) of fractions known? (check one) Yes (If yes), PBI total number of fractions Is (PBI) # (number) of fractions delivered daily known? (check one) Yes (If yes), # (number) of fractions delivered daily Partial breast irradiation method (check one) Intraop Post-op brachytherapy device (MammoSite, contoura, ClearPath, Savi) Post-op external beam (3DCRT, IMRT, Protons) 12
13 Radiation Therapy: Right Breast (page 1 of 2) INSTRUCTIONS: For date fields, UN should be entered if day (dd) is unknown; UNK should be selected if month (MMM) is unknown; Year (yyyy) cannot be entered as unknown. Cycle/Visit 0 (Baseline) (derived field) Radiation completed (check one) Yes (If no), radiation ongoing/planned (check one) Yes Type of radiation received (check one) Radiation therapy start date (dd MMM yyyy) - - Radiation therapy end date (dd MMM yyyy) - - Whole breast irradiation only Whole breast irradiation and regional nodal irradiation Partial breast irradiation Post mastectomy irradiation chest wall only Post mastectomy irradiation chest wall and regional nodes II. RADIATION DOSE TO WHOLE BREAST OR CHEST WALL Is total dose prior to boost known? (check one) Yes (If yes). total dose prior to boost. (Gy) Is total # (number) of fractions known? (check one) Yes (If yes), total number of fractions Boost to lumpectomy cavity or chest wall scar Was a boost given? (check one) Yes Is RT total dose to boost field known? (check one) Yes (If yes), RT total dose to boost field. (Gy) Is total # (number) of fractions to boost field known? (check one) Yes (If yes), total number of fractions to boost field Time point (check one) Intra-Op Post-Op II. RADIATION DOSE TO TARGETED REGIONAL NODES dal regions targeted Axillary Supraclavicular/axillary level 3 Internal mammary nodes (add a log line for each nodal region targeted) Is total dose to nodal regions known? (check one) Yes (If yes), total dose to nodal regions. (Gy) Is total # (number) of fractions known? (check one) Yes (If yes), total # (number) of fractions 13
14 Radiation Therapy: Right Breast (page 2 of 2) III. PARTIAL BREAST IRRADIATION Is (PBI) total dose delivered known? (check one) Yes (If yes), PBI total dose delivered. (Gy) Is (PBI) total # (number) of fractions known? (check one) Yes (If yes), PBI total number of fractions Is (PBI) # (number) of fractions delivered daily known? (check one) Yes (If yes), # (number) of fractions delivered daily Partial breast irradiation method (check one) Intraop Post-op brachytherapy device (MammoSite, contoura, ClearPath, Savi) Post-op external beam (3DCRT, IMRT, Protons) 14
15 On-Study: Neoadjuvant/Adjuvant Therapy Cycle/Visit 0 (Baseline) (derived field) NEOADJUVANT / ADJUVANT CHEMOTHERAPIES Neoadjuvant chemotherapy (check one) Yes Adjuvant chemotherapy (check one) Yes Last date neoadjuvant/adjuvant chemotherapy administered (dd MMM yyyy) - - Chemotherapy regimen (neo-adjuvant/adjuvant therapies) (check one) AC + T EC + T TAC FEC/CEF FAC/CAF FEC + T FAC + T CMF TC EC AC + TC 15
16 Adverse Events: Baseline Cycle/Visit 0 (Baseline) (derived field) SOLICITED ADVERSE EVENTS Adverse event term (v4.0) Lower gastrointestinal hemorrhage Upper gastrointestinal hemorrhage MedDRA AE code (CTCAE v4.0) Adverse event not evaluated Adverse event grade Intracranial hemorrhage Adverse event grade description Epistaxis Hematuria Dyspepsia Gastritis Bruising
17 Supporting Documentation: Baseline Cycle/Visit 0 (Baseline) (derived field) # Date of assessment (dd MMM yyyy) Report type Specify report type Attachment (max file size 10 MB) - _- Pathology report Browse Imaging report - _- Pathology report Clinic note Other (add a log line for each report being attached) Browse 17
18 Specimen Submission: Tissue (Baseline) Cycle/Visit 0 (Baseline) (derived field) INSTRUCTIONS: 1. See Section of the protocol for specimen requirements and shipment. 2. Please do not submit this form with specimen shipment. Specimen type Paraffin block Was specimen submitted? Yes t submitted reason (see dictionary in Rave) t submitted reason other, specify Number of specimens submitted Date specimen collected (dd MMM yyyy) - _- Date specimen shipped (dd MMM yyyy) - _- REMINDER: All specimens must be logged in BioMS. Please see the protocol for further instructions. 18
19 Specimen Submission: Blood (Baseline) Cycle/Visit 0 (Baseline) (derived field) INSTRUCTIONS: 1. See Section of the protocol for specimen requirements and shipment. 2. Please do not submit this form with specimen shipment. Specimen type EDTA whole blood Was specimen submitted? Yes t submitted reason (see dictionary in Rave) t submitted reason other, specify Date specimen collected (dd MMM yyyy) - _- Date specimen shipped (dd MMM yyyy) - _- REMINDER: All specimens must be logged in BioMS. Please see the protocol for further instructions. 19
20 Specimen Submission: Urine (Baseline) Cycle/Visit (derived field) INSTRUCTIONS: 1. See Section of the protocol for specimen requirements and shipment. 2. Please do not submit this form with specimen shipment. Specimen type Spot urine Was specimen submitted? Yes t submitted reason (see dictionary in Rave) t submitted reason other, specify Date specimen collected (dd MMM yyyy) - _- Date specimen shipped (dd MMM yyyy) - _- REMINDER: All specimens must be logged in BioMS. Please see the protocol for further instructions. 20
21 PRO/QOL: Registration Fatigue/ Uniscale Assessment Compliance Cycle/Visit 0 (Baseline) (derived field) INSTRUCTIONS: Select the primary reason the assessment was not completed. If indicated to specify further details in primary reason, complete Specify reason assessment was not completed. Reason assessment was not completed (check one) Patient refusal: patient reported physical reason Patient refusal: patient reported mental/emotional reason Patient refusal: patient said did not like content of questions Patient refusal: patient did not give a reason Patient refusal: other, specify Unable to accommodate disability or language needs, specify t administered: staff unavailable t administered: staff did not give/offer assessment to patient t administered: staff misinterpreted protocol t administered: copy of form not available Other, specify Specify reason assessment was not completed 21
22 Patient Status: Baseline Cycle/Visit 0 (Baseline) (derived field) PROTOCOL TREATMENT Will the patient proceed to protocol treatment (intervention) for the first cycle? (check one) Yes PRO/QOL ASSESSMENT(S) Did the participant complete the PRO/QOL assessment(s)? (check one) Yes (If yes), date completed (dd MMM yyyy) - - (If yes), Was a translator used to administer the questionnaire? (check one) Yes (If yes), what was the relationship of the translator? (check one) Family/friend Professional translator Other (If other), specify (If yes), what was the language? INSTRUCTIONS: If patient WILL proceed to the first Cycle/Visit of protocol treatment, do NOT complete the remainder of this form. SURVIVAL STATUS Participant vital status (check one) Alive Dead Date of most recent contact (dd MMM yyyy) - - Death date (dd MMM yyyy) - - Date of last contact or death (dd MMM yyyy) - - (derived and hidden field) Cause of death (check one) (Primary cause of death; if cause of death is due to disease progression, select Tumor) Tumor New Primary Drug-Related Other If other cause of death, specify DISEASE STATUS Was disease status evaluated during this reporting period? (check one) Yes (If yes), date of most recent disease status evaluation (dd MMM yyyy) - - Invasive Breast Cancer Recurrence Has the patient developed an invasive (local or distant) progression or recurrence that has not been previously reported? (check one) Yes New Primary Has the patient developed a new primary (breast or non-breast) that has not been previously reported? (check one) Yes DCIS Has the patient developed new DCIS that has not been previously reported? (check one) Yes 22
23 Intervention Cycle/Visit (derived field) Weight. (kg) (used for this cycle, round to nearest tenth) BMI. Did the patient have non-protocol use of aspirin or other NSAIDs during this reporting period? (check one) Yes (If yes), frequency administered (average use per week over the last 6 months) (check one) <1 time per week 1-6 times per week Daily or more Agent name Aspirin/Placebo Dose (at Day 1 this reporting period) Units of measure mg Was the patient compliant? (defined as taking >=80% of study medication) Yes Was protocol treatment modified? Yes, planned Yes, unplanned Start date (dd MMM yyyy) - _- 23
24 Intervention: Dose Modifications Cycle/Visit (derived field) Agent name Dose modification reason (CTCAE v4.0 SOC) Aspirin/Placebo 24
25 Adverse Events: Solicited (page 1 of 2) Cycle/Visit (derived field) Reporting period end date (dd MMM yyyy) - - SOLICITED ADVERSE EVENTS Adverse event term (v4.0) MedDRA AE code (CTCAE v4.0) Adverse event not evaluated Adverse event grade (highest grade this reporting period) INCLUDE GRADE 0 s Adverse event grade description AE attribution (if grade >0) Has an adverse event expedited report been submitted? Lower gastrointestinal hemorrhage (death) Unrelated Unlikely Possible Probable Definite Yes Upper gastrointestinal hemorrhage (death) Unrelated Unlikely Possible Probable Definite Yes Intracranial hemorrhage (death) Unrelated Unlikely Possible Probable Definite Yes Epistaxis (death) Hematuria (death) Dyspepsia Gastritis (death) Bruising Unrelated Unlikely Possible Probable Definite Unrelated Unlikely Possible Probable Definite Unrelated Unlikely Possible Probable Definite Unrelated Unlikely Possible Probable Definite Unrelated Unlikely Possible Probable Definite Yes Yes Yes Yes Yes 25
26 Adverse Events: Solicited (page 2 of 2) Were (other) adverse events assessed during this reporting period? (check one) Yes, and reportable adverse events occurred (go to Adverse Events: Other CRF) Yes, but no reportable adverse events occurred 26
27 Adverse Events: Other Cycle/Visit (derived field) INSTRUCTIONS: Record all adverse events beyond those solicited; record grade 2 with attribution of possible, probable or definite and all grade 3, 4 and 5 regardless of attribution. (Both hematologic and non-hematologic adverse events must be graded on this form as applicable.) Adverse event term (v4.0) MedDRA AE code (CTCAE v4.0) Adverse event grade (highest grade this reporting period) (death) Adverse event grade description AE attribution Unrelated Unlikely Possible Probable Definite Has an adverse event expedited report been submitted?* Yes (death) Unrelated Unlikely Possible Probable Definite Yes (death) Unrelated Unlikely Possible Probable Definite Yes (death) Unrelated Unlikely Possible Probable Definite Yes (death) Unrelated Unlikely Possible Probable Definite Yes (death) Unrelated Unlikely Possible Probable Definite Yes (add a log line for each adverse event reported) *See Adverse Event Section of the Protocol v.12/10/12 27
28 Supporting Documentation Cycle/Visit (derived field) # Date of assessment (dd MMM yyyy) Report type Specify report type Attachment (max file size 10 MB) - _- Imaging report Pathology report Clinic note Other Browse 28
29 Specimen Submission: Blood (24 months post registration) Cycle/Visit (derived field) INSTRUCTIONS: 3. See Section of the protocol for specimen requirements and shipment. 4. Please do not submit this form with specimen shipment. Specimen type EDTA whole blood Was specimen submitted? Yes t submitted reason (see dictionary in Rave) t submitted reason other, specify Date specimen collected (dd MMM yyyy) - _- Date specimen shipped (dd MMM yyyy) - _- REMINDER: All specimens must be logged in BioMS. Please see the protocol for further instructions. 29
30 Specimen Submission: Urine (24 months post registration) Cycle/Visit (derived field) INSTRUCTIONS: 3. See Section of the protocol for specimen requirements and shipment. 4. Please do not submit this form with specimen shipment. Specimen type Spot urine Was specimen submitted? Yes t submitted reason (see dictionary in Rave) t submitted reason other, specify Date specimen collected (dd MMM yyyy) - _- Date specimen shipped (dd MMM yyyy) - _- REMINDER: All specimens must be logged in BioMS. Please see the protocol for further instructions. 30
31 PRO/QOL: Booklet Compliance Cycle/Visit (derived field) INSTRUCTIONS: Select the primary reason the booklet was not completed. If indicated to specify further details in primary reason, complete Specify reason booklet was not completed. Reason booklet was not completed (check one) Patient refusal: patient reported physical reason Patient refusal: patient reported mental/emotional reason Patient refusal: patient said did not like content of questions Patient refusal: patient did not want to finish booklet since didn t complete study Patient refusal: patient did not give a reason Patient refusal: other, specify Unable to accommodate disability or language needs, specify t administered: staff unavailable t administered: staff did not give/offer assessment to patient t administered: staff misinterpreted protocol t administered: patient was given wrong booklet t administered: no booklets were available to give the patient visit: patient did not complete study and was not asked to return booklet visit: no clinic visit was scheduled by mistake visit: patient missed/canceled the clinic visit visit: no clinic visit due to treatment hold or delay visit: other, specify At home booklet not returned: patient did not complete study and was not asked to return booklet At home booklet not returned: patient indicated booklet was returned, but it was not received by site At home booklet not returned: reason unknown At home booklet not returned: other, specify Patient died Other, specify Specify reason booklet was not completed 31
32 Patient Status: Treatment (Intervention) Cycle/Visit (derived field) SURVIVAL STATUS Participant vital status (check one) Alive Dead Date of most recent contact (dd MMM yyyy) - - Death date (dd MMM yyyy) - - Date of last contact or death (dd MMM yyyy) - - (derived and hidden field) Cause of death (check one) (Primary cause of death; if cause of death is due to disease progression, select Tumor) Tumor New Primary Drug-Related Other If other cause of death, specify DISEASE STATUS Was disease status evaluated during this reporting period? (check one) Yes (If yes), date of most recent disease status evaluation (dd MMM yyyy) - - Invasive Breast Cancer Recurrence Has the patient developed an invasive (local or distant) progression or recurrence that has not been previously reported? (check one) Yes New Primary Has the patient developed a new primary (breast or non-breast) that has not been previously reported? (check one) Yes DCIS Has the patient developed new DCIS that has not been previously reported? (check one) Yes PROTOCOL TREATMENT Will the patient continue protocol treatment (intervention) in the subsequent cycle? (check one) Yes PRO/QOL ASSESSMENT(S) te: If PRO/QOL is expected at the current time point, answer Yes or to the following question. If PRO/QOL is not expected at the current time point, answer t applicable. Did the participant complete the PRO/QOL assessment(s)? (check one) Yes t applicable (If yes), date completed (dd MMM yyyy) - - SPECIMENS FOR BANKING Were specimens for banking submitted this cycle? (check one) Yes 32
33 tice of Invasive Breast Cancer Recurrence Cycle/Visit (derived field) Local-regional recurrence (check one) Yes (If yes), Date of local (regional) recurrence (dd MMM yyyy) - - Site(s) of local-regional recurrence Ipsilateral breast (check one) Yes Chest wall (check one) Yes Axillary node(s) (check one) Yes Internal mammary node (check one) Yes Infraclavicular node(s) (check one) Yes Supraclavicular nodes (check one) Yes Other (check one) Yes If other, specify Distant recurrence (check one) Yes (If yes), Date of distant recurrence (dd MMM yyyy) - - Site(s) of distant recurrence Bone (check one) Yes Liver (check one) Yes Lung (check one) Yes CNS (check one) Yes Other (check one) Yes If other, specify 33
34 tice of New Primary Cycle/Visit (derived field) NOTE: Do not report squamous or basal cell skin cancer, melanoma in situ, carcinoma of the cervix, or colon carcinoma in situ. NOTICE OF NEW PRIMARY Location of new primary Invasive ipsilateral breast Invasive contralateral breast Acute Myelogenous Leukemia (AML) Ovary Thyroid Uterus Colon Lung Myelodysplastic Syndrome (MDS) Acute Lymphoblastic Leukemia (ALL) Other If other, specify New primary cancer date (dd MMM yyyy) - - (add a new logline for each new primary) 34
35 tice of New DCIS Cycle/Visit (derived field) Location of DCIS Left Right Date of tissue diagnosis of DCIS (dd MMM yyyy) - - Left - - Right (Add a new logline for each new DCIS) 35
36 Off Treatment Last date protocol treatment/intervention (any modality) given (dd MMM yyyy) - - (date of last treatment (intervention) dose on this study or date decision made not to initiate protocol treatment (e.g. surgery, radiation, ablation)) Off treatment (intervention) date (dd MMM yyyy) - - (date decision was made to end active treatment or not to initiate protocol treatment (e.g. surgery, radiation, ablation) Off treatment (intervention) reason (check one) Treatment Completed Per Protocol Criteria Disease Progression, Relapse During Active Treatment Disease Progression Before Active Treatment Adverse Event/Side Effects/Complications Alternative Therapy Patient Off-Treatment For Other Complicating Disease Death On Study Patient Withdrawal/Refusal After Beginning Protocol Therapy Patient Withdrawal/Refusal Prior to Beginning Protocol Therapy Other Off treatment (intervention) reason other, specify 36
37 Patient Status: Survival and Disease Status Follow-Up Cycle/Visit (derived field) Were you able to obtain any information about the patient since the last report? (check one) Yes (If no), date of last attempt to contact patient (dd MMM yyyy) - - (If no, end form) SURVIVAL STATUS Participant vital status (check one) Alive Dead Date of most recent contact (dd MMM yyyy) - - Death date (dd MMM yyyy) - - Date of last contact or death (dd MMM yyyy) - - (derived and hidden field) Cause of death (check one) (Primary cause of death; if cause of death is due to disease progression, select Tumor) Tumor New Primary Drug-Related Other If other cause of death, specify DISEASE STATUS Was disease status evaluated during this reporting period? (check one) Yes (If yes), date of most recent disease status evaluation (dd MMM yyyy) - - Invasive Breast Cancer Recurrence Has the patient developed an invasive (local or distant) progression or recurrence that has not been previously reported? (check one) Yes New Primary Has the patient developed a new primary (breast or non-breast) that has not been previously reported? (check one) Yes DCIS Has the patient developed new DCIS that has not been previously reported? (check one) Yes FIRST NON-PROTOCOL TREATMENT Has the patent received non-protocol treatment for this cancer that has not been previously reported? (check one) Yes PRO/QOL ASSESSMENT(S) te: If PRO/QOL is expected at the current time point, answer Yes or to the following question. If PRO/QOL is not expected at the current time point, answer t applicable. Did the participant complete the PRO/QOL assessment(s)? (check one) Yes t applicable (If yes), date completed (dd MMM yyyy) - - LATE ADVERSE EVENTS Has the patient had a grade 3+ adverse event that has not been previously reported? (check one) Yes 37
38 Adverse Events: Late Adverse event term (v4.0) MedDRA AE code (CTCAE v4.0) Adverse event grade Adverse event grade description AE attribution AE start date (dd MMM yyyy) (death) Unrelated Unlikely Possible Probable Definite (death) Unrelated Unlikely Possible Probable Definite (death) Unrelated Unlikely Possible Probable Definite (death) Unrelated Unlikely Possible Probable Definite (death) Unrelated Unlikely Possible Probable Definite (death) Unrelated Unlikely Possible Probable Definite - - (add a log line for each late adverse event reported) (death) Unrelated Unlikely Possible Probable Definite
39 Consent Withdrawal INSTRUCTIONS: If a study participant is refusing further study treatment, document the refusal by completing an Off Treatment form, and select Form added in error. Form added in error INSTRUCTIONS: Select consent withdrawal for all follow-up if the participant is withdrawing consent for all further followup, this would include clinical, specimen and QOL, and any additional follow-up. Select type(s) of withdrawal below (check all that apply) Consent withdrawal for QOL (patient reported outcomes) only Consent withdrawal for all specimens only Consent withdrawal for all follow-up 39
40 Consent Withdrawal: QOL Only INSTRUCTIONS: A Consent Withdrawal: QOL Only form should be completed if a study participant is not willing to complete QOL assessments. Date study participant withdrew consent (dd MMM yyyy) - - Site investigator notified (check if notified) 40
41 Consent Withdrawal: Specimen Only INSTRUCTIONS: A Consent Withdrawal: Specimen Only form should be completed if a study participant is no longer willing to have their specimen(s) used for research. Date study participant withdrew consent (dd MMM yyyy) - - Site investigator notified (check if notified) 41
42 Consent Withdrawal: All Follow-Up INSTRUCTIONS: A Consent Withdrawal: All Follow-Up form should be completed if the study participant is not willing to be contacted for further follow-up. Date study participant withdrew consent (dd MMM yyyy) - - Site investigator notified (check if notified) 42
43 Lost to Follow-Up Date study participant deemed lost to follow-up (dd MMM yyyy) - - INSTRUCTIONS: A study participant can be declared lost if attempts have been unsuccessful after 2 years without contact. Please indicate which steps below were taken to contact the study participant. Researched Social Security Death Index and found no information for this study participant, specify most recent date (dd MMM yyyy) - - Sent certified or registered international letter to last known address, specify most recent date sent (dd MMM yyyy) - - Result of certified or registered international letter Other method, specify Letter returned unclaimed or marked addressee unknown response 1 month after confirmed receipt of letter Other Site Investigator notified OFFICE USE ONLY: Central reviewer agrees study participant has been deemed lost to follow-up according to the required criteria 43
ACRIN 6666 Therapeutic Surgery Form
S1 ACRIN 6666 Therapeutic Surgery Form 6666 Instructions: Complete a separate S1 form for each separate area of each breast excised with the intent to treat a cancer (e.g. each lumpectomy or mastectomy).
More informationSurgery for Breast Cancer
Surgery for Breast Cancer 1750 Mastectomy - Petit 1894 Radical mastectomy Halsted Extended, Super radical mastectomy 1948 Modified radical mastectomy Patey 1950-60 WLE & RT Baclesse, Mustakallio 1981-85
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationConservative Surgery and Radiation Stage I and II Breast Cancer
Conservative Surgery and Radiation Stage I and II Breast Cancer Variant 1: Premenopausal 41-year-old woman, 1.1-cm GII IDC, upper outer quadrant (UOQ), ER/PR ( ), HER2 ( ), primary excised with lumpectomy,
More informationBreast Surgery When Less is More and More is Less. E MacIntosh, MD June 6, 2015
Breast Surgery When Less is More and More is Less E MacIntosh, MD June 6, 2015 Presenter Disclosure Faculty: E. MacIntosh Relationships with commercial interests: None Mitigating Potential Bias Not applicable
More informationClinical Trials of Proton Therapy for Breast Cancer. Andrew L. Chang, MD 張維安 Study Chair
Clinical Trials of Proton Therapy for Breast Cancer Andrew L. Chang, MD 張維安 Study Chair AndrewLChangMD@gmail.com Disclosure Proton Center Development Corporation Scripps San Diego Proton Therapy Center
More informationAdvances in Localized Breast Cancer
Advances in Localized Breast Cancer Melissa Camp, MD, MPH and Fariba Asrari, MD June 18, 2018 Moderated by Elissa Bantug 1 Advances in Surgery for Breast Cancer Melissa Camp, MD June 18, 2018 2 Historical
More informationANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to:
1 ANNEX 1 OBJECTIVES At the completion of the training period, the fellow should be able to: 1. Breast Surgery Evaluate and manage common benign and malignant breast conditions. Assess the indications
More informationSurgical Advances in the Treatment of Breast Cancer. Laura Kruper, MD, MSCE Chief, Breast Surgery
Surgical Advances in the Treatment of Breast Cancer Laura Kruper, MD, MSCE Chief, Breast Surgery Nothing to disclose DISCLOSURE LESS IS MORE Radiation Lymph nodes Reconstruction Less is More! Radiation
More informationCompleting the Puzzle AJCC TNM Staging Breast. Nicole Catlett, CTR 2017 Kentucky Cancer Registry Fall Conference, September 21 & 22, 2017
Completing the Puzzle AJCC TNM Staging Breast Nicole Catlett, CTR 2017 Kentucky Cancer Registry Fall Conference, September 21 & 22, 2017 OBJECTIVES Understanding of Breast TNM staging Identify clinical
More informationAdvances in Breast Surgery. Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015
Advances in Breast Surgery Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015 Objectives Understand the surgical treatment of breast cancer Be able to determine when a lumpectomy
More informationCorporate Medical Policy
Corporate Medical Policy Breast Brachytherapy for Accelerated Partial Breast Radiotherapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: breast_brachytherapy_for_accelerated_partial_breast_radiotherapy
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process
Quality ID #264: Sentinel Lymph Node Biopsy for Invasive Breast Cancer National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Appropriate Use of Healthcare 2019 COLLECTION TYPE:
More informationSTAGE CATEGORY DEFINITIONS
CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery TX Tis Tis (DCIS) Tis (LCIS) Tis (Paget s) T1 T1mi T1a T1b T1c a b c
More informationCancer Endorsement Maintenance 2011-Maintenance Measures
Measure Number Title Description Measure Steward 0210 Proportion receiving chemotherapy in the last 14 days of life 0211 Proportion with more than one emergency room visit in the last days of life 0212
More informationNational Mastectomy & Breast Reconstruction Audit Datasheet - Mastectomy +/- Immediate Reconstruction
Patient Registration data Surname Forename NHS/Private Hospital Number Date of birth Postcode Ethnicity Patient-reported outcomes consent Has this patient consented to being sent outcome questionnaires?
More informationCase Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.
Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Background: 46 year old married premenopausal female with dense breasts has noticed
More informationClinical Outcome of Reconstruction With Tissue Expanders for Patients With Breast Cancer and Mastectomy
Clinical Outcome of Reconstruction With Tissue Expanders for Patients With Breast Cancer and Mastectomy Mitsui Memorial Hospital Department of Breast and Endocine surgery Daisuke Ota No financial support
More informationWelcome to. American College of Surgeons. Clinical Research Program (ACS-CRP) Breast Surgical Trial Webinar
American College of Surgeons Clinical Research Program Kelly K. Hunt, M.D. Program Director Welcome to American College of Surgeons Clinical Research Program (ACS-CRP) Breast Surgical Trial Webinar Moderator:
More informationCase Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.
Case Scenario 1 1/3/11 A 57 year old white female presents for her annual mammogram and is found to have a suspicious area of calcification, spread out over at least 4 centimeters. She is scheduled to
More informationRADIOTHERAPY IN BREAST CANCER :
RADIOTHERAPY IN BREAST CANCER : PAST, PRESENT, FUTURE Dr Jyotirup Goswami Consultant Radiation Oncologist Narayana Cancer Institute Narayana Superspecialty Hospital Breast cancer is the classic paradigm
More informationCase Scenario 1 History and Physical 3/15/13 Imaging Pathology
Case Scenario 1 History and Physical 3/15/13 The patient is an 84 year old white female who presented with an abnormal mammogram. The patient has a five year history of refractory anemia with ringed sideroblasts
More informationQuality ID #264: Sentinel Lymph Node Biopsy for Invasive Breast Cancer National Quality Strategy Domain: Effective Clinical Care
Quality ID #264: Sentinel Lymph de Biopsy for Invasive Breast Cancer National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process
More informationCase Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.
Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Background: 46 year old married premenopausal female with dense breasts has noticed
More informationResults of the ACOSOG Z0011 Trial
DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival
More informationMeasure #264: Sentinel Lymph Node Biopsy for Invasive Breast Cancer National Quality Strategy Domain: Effective Clinical Care
Measure #264: Sentinel Lymph Node Biopsy for Invasive Breast Cancer National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY DESCRIPTION: The percentage
More informationEvolution of Breast Surgery
Evolution of Breast Surgery Natasha Rueth MD Surgical Oncologist Piper Breast Center and Alina Health Surgical Specialists Minneapolis, MN Definitions Radical Mastectomy: Removal of breast, chest muscles,
More informationPMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center
PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic
More informationBREAST CANCER SURGERY. Dr. John H. Donohue
Dr. John H. Donohue HISTORY References to breast surgery in ancient Egypt (ca 3000 BCE) Mastectomy described in numerous medieval texts Petit formulated organized approach in 18 th Century Improvements
More informationSeventh Edition Staging 2017 Breast
Seventh Edition Staging 2017 Breast Donna M. Gress, RHIT, CTR Validating science. Improving patient care. No materials in this presentation may be repurposed in print or online without the express written
More informationMalignant Breast disorders
Malignant Breast disorders RISK FACTORS FOR BREAST CANCER Family Hx.: first- and second-degree relatives with breast cancer and their age at diagnosis. RISK FACTORS FOR BREAST CANCER (cont.) Hormonal Risk
More informationBreast Conservation Therapy
May 18, 2018 Breast Conservation Therapy One Treatment No Longer Fits All Presenter: Paul B. Fowler, MD Radiation Oncology, MGSH/MUMH 1 Objectives: 1. Define stages of breast cancer that are candidates
More informationVersion STUDY PROTOCOL IRMA
Version 30.07.2008 STUDY PROTOCOL IRMA BREAST CANCER WITH LOW RISK OF LOCAL RECURRENCE: PARTIAL AND ACCELERATED RADIATION WITH THREE-DIMENSIONAL CONFORMAL RADIOTHERAPY (3DCRT) VS. STANDARD RADIOTHERAPY
More informationSan Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy
San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationHow can surgeons help the Radiation Oncologists?
How can surgeons help the Radiation Oncologists? Lorna Weir BC Surgical Oncology fall breast cancer update Oct 24, 2009 Disclosure no conflict of interest Outline Introduction OR reports Marking of surgical
More informationPLACE LABEL HERE. Radiation Therapy Oncology Group Phase II - SBRT - Medically Inoperable I /II NSCLC Follow-up Form. RTOG Study No.
Radiation Therapy Oncology Group Phase II - SBRT - Medically Inoperable I /II NSCLC Follow-up Form RTOG Study No. 0813 Case # Name RTOG Patient ID INSTRUCTIONS: Submit this form at the appropriate followup
More informationCertified Breast Care Nurse (CBCN ) Test Content Outline (Effective 2018)
Certified Breast Care Nurse (CBCN ) Test Content Outline (Effective 2018) I. Coordination of Care - 26% A. Breast health, screening, early detection, risk assessment and reduction 1. Issues related to
More informationW3C Life Sciences: Clinical Observations Interoperability: EMR + Clinical Trials Use-case for EMR + Clinical Trials Interoperability
W3C Life Sciences: Clinical Observations Interoperability: EMR + Clinical Trials Use-case for EMR + Clinical Trials Interoperability Background: The key issue is to investigate whether some of the data
More informationNSABP B-55/BIG Lynne Suhayda, RN, MSEd. Director, Clinical Coordinating Department. NRG Oncology - Pittsburgh, Pennsylvania
NSABP B-55/BIG 6-13 Lynne Suhayda, RN, MSEd. Director, Clinical Coordinating Department NRG Oncology - Pittsburgh, Pennsylvania NRG Oncology Meeting July 15, 2016 Lynne Suhayda, RN, MSEd. No Financial
More informationChapter 2 Staging of Breast Cancer
Chapter 2 Staging of Breast Cancer Zeynep Ozsaran and Senem Demirci Alanyalı 2.1 Introduction Five decades ago, Denoix et al. proposed classification system (tumor node metastasis [TNM]) based on the dissemination
More informationEducational Goals and Objectives for Rotations on: Breast, Wound and Plastic Surgery
Educational Goals and Objectives for Rotations on: Breast, Wound and Plastic Surgery Goal The goal of the Breast Surgery rotation is to develop the knowledge, skills and attitudes necessary to evaluate,
More informationClassification System
Classification System A graduate of the Breast Oncology training program should be able to care for all aspects of disease and/or provide comprehensive management. When referring to a discipline of training
More informationNational Center of Oncology - Yerevan, Armenia
- Yerevan, Armenia General Information New breast cancer cases treated per year 450 Breast multidisciplinarity team members 13 Radiologists, surgeons, pathologists, medical oncologists, radiotherapists
More informationBreast cancer reconstruction surgery (immediate and delayed) across Ontario: Patient indications and appropriate surgical options
A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Breast cancer reconstruction surgery (immediate and delayed) across Ontario: Patient indications and appropriate
More informationCombined chemotherapy and Radiotherapy for Patients with Breast Cancer and Extensive Nodal Involvement.
Combined chemotherapy and Radiotherapy for Patients with Breast Cancer and Extensive Nodal Involvement. Ung O, Langlands A, Barraclough B, Boyages J. J Clin Oncology 13(2) : 435-443, Feb 1995 STUDY DESIGN
More informationEvolution of Regional Nodal Management of Breast Cancer
Evolution of Regional Nodal Management of Breast Cancer Bruce G. Haffty, MD Director (Interim) Rutgers Cancer Institute of New Jersey Professor and Chair Department of Radiation Oncology Rutgers, The State
More informationBreast Surgery: Yesterday, Today and Tomorrow
Breast Surgery: Yesterday, Today and Tomorrow Baptist Hospital Gladys L. Giron, MD, FACS October 11,2014 Homestead Hospital Baptist Children s Hospital Doctors Hospital Baptist Cardiac & Vascular Institute
More informationClinical Trial Results Database Page 1
Page 1 Sponsor Novartis UK Limited Generic Drug Name Letrozole/FEM345 Therapeutic Area of Trial Localized ER and/or PgR receptor positive breast cancer Study Number CFEM345EGB07 Protocol Title This study
More informationProtocol of Radiotherapy for Breast Cancer
107 年 12 月修訂 Protocol of Radiotherapy for Breast Cancer Indication of radiotherapy Indications for Post-Mastectomy Radiotherapy (1) Axillary lymph node 4 positive (2) Axillary lymph node 1-3 positive:
More informationClinica Medellin - Medellin, Colombia
- Medellin, Colombia General Information New breast cancer cases treated per year 150 Breast multidisciplinarity team members 12 Radiologists, surgeons, pathologists, medical oncologists, radiotherapists
More informationPage 1. AHN-JHU Breast Cancer Symposium. Novel Local Regional Clinical Trials. Background. Neoadjuvant Chemotherapy Benefit.
AHN-JHU Breast Cancer Symposium Novel Local Regional Clinical Trials March 22, 2019 Thomas B. Julian, MD, FACS Associate Medical Director, Cancer Program Development, ANH Cancer Institute Background In
More informationNew Technologies in Radiation Oncology. Catherine Park, MD, MPH Advocate Good Shepherd Hospital
New Technologies in Radiation Oncology Catherine Park, MD, MPH Advocate Good Shepherd Hospital Breast Radiation Early Stage Breast Cancer Whole Breast Radiation Delivered to the whole breast Boost to the
More informationWhat is the recommended regimen for adjuvant radiation therapy? Tata Memorial Centre s opinion is summarized as follows:
February 3 rd 2015 Dear Ms., Thank you for reaching out to Tata Memorial Centre for an expert opinion in regard to assessing your treatment options. Navya Network is pleased to offer this online consultation
More informationEvolving Practices in Breast Cancer Management
Evolving Practices in Breast Cancer Management The Georgia Tumor Registrars Association 2016 Priscilla R. Strom, MD, FACS Objectives 1. understand newer indications for neoadjuvant treatment 2. understand
More information03/14/2019. Postmastectomy radiotherapy; the meta-analyses, and the paradigm change to altered fractionation Mark Trombetta M.D.
radiotherapy; the meta-analyses, and the paradigm change to altered fractionation Mark Trombetta M.D. Division of Radiation Oncology Allegheny Health Network Cancer Institute Professor of Radiation Oncology
More informationClinical outcomes of patients treated with accelerated partial breast irradiation with high-dose rate brachytherapy: Scripps Clinic experience
Original Article Clinical outcomes of patients treated with accelerated partial breast irradiation with high-dose rate brachytherapy: Scripps Clinic experience Rachel Murray 1, Fantine Giap 2, Ray Lin
More informationBalancing Evidence and Clinical Practice in the Treatment of Localized Breast Cancer May 5, 2006
Balancing Evidence and Clinical Practice in the Treatment of Localized Breast Cancer May 5, 2006 Deborah Hamolsky MS, RN : DCIS Carol Franc Buck Breast Care Center UCSF Comprehensive Cancer Center Jane
More informationOFCCR CLINICAL DIAGNOSIS AND TREATMENT FORM
OFCCR CLINICAL DIAGNOSIS AND TREATMENT FORM Name: _, OFCCR # _ OCGN # _ OCR Group # _ HIN# Sex: MALE FEMALE UNKNOWN Date of Birth: DD MMM YYYY BASELINE DIAGNOSIS & TREATMENT 1. Place of Diagnosis: Name
More informationRetrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer.
Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer. Goal of the study: 1.To assess whether patients at Truman
More information制定阮綜合醫療社團法人阮綜合醫院乳癌 (Breast Cancer) 治療共識
2006.03.09 制定阮綜合醫療社團法人阮綜合醫院乳癌 (Breast Cancer) 治療共識 2007.10.01 修訂 2009.04.22 修訂 2010.04.07 審閱 LCIS (Lobular Carcinoma in Situ) 2011.12.07 修訂 2012.03.07 修訂 Diagnosis Workup Risk Reduction Surveillance Biopsy
More informationBreast Cancer: Current Approaches to Diagnosis and Treatment
Breast Cancer: Current Approaches to Diagnosis and Treatment Barbara L. Smith, MD, Ph.D. Massachusetts General Hospital Division of Surgical Oncology No Disclosures Incidence of Breast Cancer USA 2018
More informationTreatment Planning for Breast Cancer: Contouring Targets. Julia White MD Professor
Treatment Planning for Breast Cancer: Contouring Targets Julia White MD Professor Outline 1. RTOG Breast Cancer Atlas 2. Target development on Clinical Trials Whole Breast Irradiation 2-D Radiotherapy
More informationHOSPITAL MODELO - LA CORUÑA, Spain
- LA CORUÑA, Spain General Information New breast cancer cases treated per year 150 Breast multidisciplinarity team members 8 Radiologists, surgeons, pathologists, medical oncologists, radiotherapists
More informationMultidisciplinary management of breast cancer
Multidisciplinary management of breast cancer C. Polgár 1,2 1 National Institute of Oncology 2 Semmelweis University Department of Oncology Incidence of breast cancer in Hungary 2014 Female population
More informationPatient Last Name First Name Middle Name. Home Address City State Zip. Date of Birth Age Social Security # - - Cell Phone Home Phone Work Phone
Date Patient Last Name First Name Middle Name Gender (circle): Male Female Other: Marital Status (circle): Single Married Divorced Widowed Separated Home Address City State Zip Date of Birth Age Social
More informationBreast Cancer Diagnosis, Treatment and Follow-up
Breast Cancer Diagnosis, Treatment and Follow-up What is breast cancer? Each of the body s organs, including the breast, is made up of many types of cells. Normally, healthy cells grow and divide to produce
More informationKey Ouestions. to ask your medical oncology team after being diagnosed with breast cancer
Key Ouestions to ask your medical oncology team after being diagnosed with breast cancer tips to make your visit with the physician a success: Bring this list of questions, a pen and paper to write down
More informationDyson Center for Cancer Care - Poughkeepsie, New York, United States of America
- Poughkeepsie, New York, United States of America General Information New breast cancer cases treated per year 323 Breast multidisciplinarity team members 14 Radiologists, surgeons, pathologists, medical
More informationJose A Torres, MD 1/12/2017
Jose A Torres, MD 1/12/2017 Background Globally leading cause of cancer related death in women ~249,000 Americans diagnosed with invasive breast cancer ~40,890 will die of their disease Breast cancer risk
More informationMammo-50 Eligibility Queries
Mammo-50 Eligibility Queries Are patients who have received either neo-adjuvant or adjuvant chemo, radiotherapy or been part of another trial, ie OPTIMA, FAST FORWARD excluded from entry? Any patients
More informationCork University Hospital - Cork, Ireland
- Cork, Ireland General Information New breast cancer cases treated per year 336 Breast multidisciplinarity team members 25 Radiologists, surgeons, pathologists, medical oncologists, radiotherapists and
More informationSan Donato Hospital - Azienda USL TOSCANA SUDEST Arezzo - Arezzo, Italy
San Donato Hospital - Azienda USL TOSCANA SUDEST Arezzo - Arezzo, Italy General Information New breast cancer cases treated per year 255 Breast multidisciplinarity team members 18 Radiologists, surgeons,
More informationSurgery Choices for Breast Cancer
Surgery Choices for Breast Cancer Surgery Choices for Women with DCIS or Breast Cancer As a woman with DCIS (ductal carcinoma in situ) or breast cancer that can be removed with surgery, you may be able
More informationInvasive Breast Cancer
Invasive Breast Cancer Eileen Rakovitch MD MSc FRCPC Sunnybrook Health Sciences Centre Medical Director, Louise Temerty Breast Cancer Centre LC Campbell Chair in Breast Cancer Research Associate Professor,
More informationCurrent Status of Accelerated Partial Breast Irradiation. Julia White MD Professor, Radiation Oncology
Current Status of Accelerated Partial Breast Irradiation Julia White MD Professor, Radiation Oncology I have no disclosures relative to the presented material Agenda ABPI Timeline APBI by Method Clinical
More informationEvaluation of the Axilla Post Z-0011 Trial New Paradigm
Evaluation of the Axilla Post Z-0011 Trial New Paradigm Belinda Curpen, MD, FRCPC; Tetyana Dushenkovska; Mia Skarpathiotakis MD, FRCPC; Carrie Betel, MD, FRCPC; Kalesha Hack, MD, FRCPC; Lara Richmond,
More informationDebate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest
Debate Axillary dissection - con Prof. Dr. Rodica Anghel Institute of Oncology Bucharest Summer School of Oncology, third edition Updated Oncology 2015: State of the Art News & Challenging Topics Bucharest,
More informationBreast Cancer Breast Managed Clinical Network
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Less than 4 positive lymph nodes Adjuvant Treatment ER Positive HER2 Negative (see page 2 & 3 ) HER2 Positive
More informationBarlavento Medical Centre - Portimão, Portugal
- Portimão, Portugal General Information New breast cancer cases treated per year 150 Breast multidisciplinarity team members 9 Radiologists, surgeons, pathologists, medical oncologists, radiotherapists
More informationDescriptor Definition Author s notes TNM descriptors Required only if applicable; select all that apply multiple foci of invasive carcinoma
S5.01 The tumour stage and stage grouping must be recorded to the extent possible, based on the AJCC Cancer Staging Manual (7 th Edition). 11 (See Tables S5.01a and S5.01b below.) Table S5.01a AJCC breast
More informationRUTGERS CANCER INSTITUTE OF NEW JERSEY - ROBERT WOOD JOHNSON MEDICAL SCHOOL INTERDISCIPLINARY BREAST SURGERY FELLOWSHIP CORE EDUCATIONAL OBJECTIVES
RUTGERS CANCER INSTITUTE OF NEW JERSEY - ROBERT WOOD JOHNSON MEDICAL SCHOOL INTERDISCIPLINARY BREAST SURGERY FELLOWSHIP CORE EDUCATIONAL OBJECTIVES At the completion of Breast Fellowship training, the
More information1. Screening, Diagnosis and Surgical Management of Breast Cancer
1. Screening, Diagnosis and Surgical Management of Breast Cancer Dr Melanie Walker, MBBS, FRACS (Breast Surgeon) Oncoplastic Breast Surgery Combination of optimal cancer surgery with plastic surgical techniques
More informationLesion Imaging Characteristics Mass, Favoring Benign Circumscribed Margins Intramammary Lymph Node
Lesion Imaging Characteristics Mass, Favoring Benign Circumscribed Margins Intramammary Lymph Node Oil Cyst Mass, Intermediate Concern Microlobulated Margins Obscured Margins Mass, Favoring Malignant Indistinct
More informationCancer. Savita Dandapani
New Modalities for Breast Cancer Savita Dandapani Disclosures Accuray Talk at ASTRO 10/2015. Xoft provided slides for the partial breast radiation equipment. Early Stage: Deep Inspiratory Breath Hold (DIBH)
More informationCivic Hospital of Sanremo ASL 1 Imperiese - Sanremo, Italy
- Sanremo, Italy General Information New breast cancer cases treated per year 188 Breast multidisciplinarity team members 10 Radiologists, surgeons, pathologists, medical oncologists, radiotherapists and
More informationACCELERATED BREAST IRRADIATION EVOLVING PARADIGM FOR TREATMENT OF EARLY STAGE BREAST CANCER
ACCELERATED BREAST IRRADIATION EVOLVING PARADIGM FOR TREATMENT OF EARLY STAGE BREAST CANCER KHANH NGUYEN, MD, MA DEPARTMENT OF RADIATION ONCOLOGY BAYHEALTH CANCER CENTER BREAST CANCER STATISTICS Most common
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology
More informationAppendix ZOOM Etude pour site internet
Appendix ZOOM Etude pour site internet Indication Traitement adjuvant pour des patients présentant une mutation germinale des gènes BRCA1/2 et un risque élevé de cancer du sein primaire HER2 négatif Title
More informationObjectives Critically review presentations on 1. Local therapy 2. Adjuvant chemotherapy for isolated local regional recurrence 3. The optimal duration
Objectives Critically review presentations on 1. Local therapy 2. Adjuvant chemotherapy for isolated local regional recurrence 3. The optimal duration of endocrine therapy 4. Advances in HER2 directed
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
- Original Issue Date (Created): November 22, 2011 Most Recent Review Date (Revised): May 20, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS
More informationSubject ID: I N D # # U A * Consent Date: Day Month Year
IND Study # Eligibility Checklist Pg 1 of 15 Instructions: Check the appropriate box for each Inclusion and Exclusion Criterion below. Each criterion must be marked and all protocol criteria have to be
More informationMamma Centrum / Zelený Pruh - Prague, Czech Republic
- Prague, Czech Republic General Information New breast cancer cases treated per year 490 Breast multidisciplinarity team members 29 Radiologists, surgeons, pathologists, medical oncologists, radiotherapists
More informationTable of contents. Page 2 of 40
Page 1 of 40 Table of contents Introduction... 4 1. Background Information... 6 1a: Referral source for the New Zealand episodes... 6 1b. Invasive and DCIS episodes by referral source... 7 1d. Age of the
More informationAlexandrovska Hospital - Sofia, Bulgaria
- Sofia, Bulgaria General Information New breast cancer cases treated per year 190 Breast multidisciplinarity team members 8 Radiologists, surgeons, pathologists, medical oncologists, radiotherapists and
More informationQuality ID #263: Preoperative Diagnosis of Breast Cancer National Quality Strategy Domain: Effective Clinical Care
Quality ID #263: Preoperative Diagnosis of Breast Cancer National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION:
More informationAxillary Reverse Mapping to Reduce the Incidence of Lymphedema
Axillary Reverse Mapping to Reduce the Incidence of Lymphedema Nathalie Johnson,MD,FACS Medical Director, Legacy Cancer Institute and Breast Health Centers Portland,Oregon Objectives for Learning Understand
More informationRadiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
More information